Australien - engelska - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - interferon alfa-2a -

Australien - engelska - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - interferon alfa-2a -

Australien - engelska - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - susoctocog alfa, quantity: 500 u/ml - injection - excipient ingredients: - for the treatment of bleeding episodes in adults with acquired haemophilia a.,safety and efficacy of obizur have not been established in patients with baseline anti- porcine factor viii inhibitor titre greater than 20 bu.,obizur is not indicated for the treatment of congenital haemophilia a or von willebrand disease.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

biomarin pharmaceutical australia pty ltd - elosulfase alfa, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: arginine hydrochloride; monobasic sodium phosphate monohydrate; sodium acetate trihydrate; water for injections; polysorbate 20; sorbitol - vimizim is indicated for the treatment of mucopolysaccharidosis type iva (mps iva; morquio a syndrome).

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - efmoroctocog alfa, quantity: 1000 iu - drug delivery system - excipient ingredients: - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - efmoroctocog alfa, quantity: 2000 iu - drug delivery system - excipient ingredients: - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - efmoroctocog alfa, quantity: 750 iu - drug delivery system - excipient ingredients: - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - efmoroctocog alfa, quantity: 1500 iu - drug delivery system - excipient ingredients: - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - efmoroctocog alfa, quantity: 250 iu - drug delivery system - excipient ingredients: - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - efmoroctocog alfa, quantity: 3000 iu - drug delivery system - excipient ingredients: - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.